UNSPSC 51422341: Dexamethasone pivalate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K182597N9C, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone pivalate, which bears US NIH Compound Identifier 63040. European Medicines Agency schedules Dexamethasone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01613MIG.

UNSPSC 51422341 Dexamethasone pivalate is a Commodity code that nominally covers a specific corticosteroid pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with the code's actual scope. The two recent opportunities in the dataset—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—do not involve dexamethasone pivalate procurement. The naloxone opportunity is an emergency-response pharmaceutical distinct from corticosteroids, while the Texas RFI addresses pharmacy program structure and vendor capacity rather than specific drug products. State and local procurement activity under this code appears limited and disconnected from the commodity's nominal definition, suggesting either miscoding in source systems or insufficient recent dexamethasone pivalate demand to generate dedicated solicitations.

Geographic activity is confined to Florida and Texas in the recent dataset, with the only concrete purchase opportunity originating from Seminole County, Florida—an IFB (No. IFB60459723LAS) released June 30, 2026, with response due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year term with one-year renewal option. The Texas HHS Commission's April 3, 2026 RFI represents exploratory market research rather than a committed procurement vehicle. No other state or local jurisdictions appear in the recent-opportunities block. The mismatch between the code's pharmaceutical definition and the actual solicitations—combined with the absence of dexamethasone pivalate procurement signals—indicates this code generates negligible relevant activity for vendors in the corticosteroid or specialty-pharmaceutical supply chain at the state and local level.